Hyloris Pharmaceuticals SA (EBR:HYL)
Belgium · Delayed Price · Currency is EUR 4.500
-0.020 (-0.44%)
Jul 1, 2026, 5:28 PM CET
Hyloris Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Hyloris Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of €12.30. The average 1-year stock price forecast is 173.33% higher than the current stock price, while the lowest is €6.00 (+33.33%) and the highest is €20.40 (+353.33%).
Price Target: €12.30 (+173.33%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Hyloris Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 3 |
Financial Forecast
Revenue This Year
22.04M
from 7.94M
Increased by 177.64%
Revenue Next Year
56.94M
from 22.04M
Increased by 158.30%
EPS This Year
-0.32
from -0.26
EPS Next Year
0.46
from -0.32
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 41.8M | ||
| Avg | 22.0M | ||
| Low | 9.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 426.5% | ||
| Avg | 177.6% | ||
| Low | 20.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.08 | ||
| Avg | -0.32 | ||
| Low | -0.55 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |